FDA clarifies policies for compounders as national GLP-1 supply …
Oct 22, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
New Multi-Society GLP-1 Clinical Practice Guidance Released
Oct 29, 2024 · CHICAGO – Most patients should continue taking their glucagon-like peptide-1 (GLP-1) receptor agonists before elective surgery, suggests new clinical guidance released by the American Society of Anesthesiologists (ASA), American Gastroenterological Association, American Society for Metabolic and Bariatric Surgery, International Society of ...
FDA Approves First Generic of Once-Daily GLP-1 Injection to …
FDA approved the first generic referencing Victoza (liraglutide injection) 18 mg/3 mL, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in...
Research shows GLP-1 drugs are effective but complex - UChicago …
May 30, 2024 · While experts caution against overusing GLP-1RAs or viewing them as a universal cure-all for obesity, physicians and researchers agree that the drugs are highly effective for weight management and Type 2 diabetes treatment.
GLP-1 Drug Liraglutide May Protect Against Dementia
PHILADELPHIA, July 30, 2024 — A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial data reported today at the Alzheimer’s Association International Conference ® (AAIC ®) …
Special Report: Potential Strategies for Addressing GLP-1 and Dual …
Apr 7, 2023 · Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 (1).
New hope for binge eating and bulimia: GLP-1 drugs could be the …
Mar 4, 2024 · Glucagon-like peptide-1 (GLP-1) is a hormone and neuropeptide produced in the intestine and brain. This hormone inhibits appetite, reduces food intake, reduces body weight, and stimulates...
Shortages impacting access to glucagon-like peptide 1 receptor …
Jan 29, 2024 · In the past year, global shortages of products indicated to manage diabetes type II and sometimes also approved for weight loss, known as glucagon-like peptide 1 receptor agonist (GLP-1-RA) products, have been associated with an increase in reports of falsified GLP-1-RA.
Glucagon-like peptide-1 receptor: mechanisms and advances in …
Sep 18, 2024 · We introduce recent studies that demonstrate the remarkable performance of GLP-1RAs in slowing the progression of neurodegenerative diseases, reducing inflammation, and enhancing cardiovascular...
Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists
The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized the therapeutic landscape for cardiometabolic disease. Newer, more potent GLP-1 RAs (eg, semaglutide) and dual GLP-1/glucose-dependent insulinotropic peptide agonists (eg, tirzepatide) substantially reduce body weight by 10% to 20%.